In Italy between 27 December 2020 and 26 March 2022 there were 134,361 reports of suspected adverse reactions to the Covid vaccine out of a total of 135,849,988 doses administered, equal to a reporting rate of 99 per 100,000 doses, of which 82.1% referred to non-serious events, such as injection site pain, fever, asthenia / fatigue, muscle aches. This is what emerges from the 11th report of the Italian Medicines Agency (Aifa) on the surveillance of anti Covid-19 vaccines, relating to the reports registered in the National Pharmacovigilance Network for the five vaccines in use in the current vaccination campaign. The reporting rates for the second dose – the report underlines – are lower than those for the first and even lower for the third dose. The population exposed to the 4th dose is still limited. Serious reports correspond to 17.8% of the total, with a rate of 18 serious events per 100,000 doses administered. As reported in previous reports, regardless of the vaccine, dose and type of event, the reaction occurred in most cases (approximately 72%) on the same day of vaccination or the next day and only more rarely beyond 48 hours. . Comirnaty (Pfizer) is the vaccine currently most used in the Italian vaccination campaign (65.2%), followed by Spikevax (Moderna 24.7%), Vaxzevria (Astrazeneca 9.0%), Covid-19 Vaccino Janssen (Johnson & Johnson 1 , 1%) and Nuvaxovid (Novavax 0.02%), in use since February 28, 2022. The distribution of reports by type of vaccine follows that highlighted in previous Reports: Comirnaty 66.5%, Vaxzevria 17.7%, Spikevax 14 , 5%, Covid-19 vaccine Janssen 1.3%, Nuvaxovid 0.03%. For all vaccines – concludes Aifa – the most reported adverse events are: fever, fatigue, headache, muscle / joint pain, chills, gastro-intestinal disorders, vegetative reactions, fatigue, local reaction or pain at the injection site.